At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCRX Pacira Pharmaceuticals
Pre-Market Trading 12-23 04:22:51 EST
18.98
-0.59
-3.01%
High19.80
Low18.73
Vol3.17M
Open19.07
D1 Closing19.57
Amplitude5.47%
Mkt Cap876.37M
Tradable Cap866.90M
Total Shares46.17M
T/O60.38M
T/O Rate6.94%
Tradable Shares45.67M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Here's Why Pacira (PCRX) is a Strong Momentum Stock
BRIEF-Doma Perpetual Capital Management Intends To Nominate Four Highly Qualified, Independent Director Candidates At 2025 Annual Meeting Of Pacira Biosciences
Doma Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira Biosciences, Inc.
DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.